AI Insights

Artificial Intelligence Drug Design Market Hits New High |

Published

2 weeks ago

August 18, 2025

Artificial Intelligence Drug Design Market

HTF MI just released the Global Artificial Intelligence Drug Design Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study’s segmentation by important regions. The market is currently expanding its reach.

Major Giants in Artificial Intelligence Drug Design Market are:

Insilico Medicine (USA), BenevolentAI (UK), Atomwise (USA), Exscientia (UK), Cloud Pharmaceuticals (USA), Berg LLC (USA), Relay Therapeutics (USA), Schrödinger (USA), Numerate (USA), IBM Watson Health (USA), Microsoft (USA), Google Health (USA), Pfizer (USA), Merck (USA), Novo Nordisk (Denmark)

Request PDF Sample Copy of Report: (Including Full Toc, List of Tables & Figures, Chart) @

👉 https://www.htfmarketinsights.com/sample-report/4369664-artificial-intelligence-drug-design-market?utm_source=Vaishali_OpenPR&utm_id=Vaishali

HTF Market Intelligence projects that the global Artificial intelligence drug design market will expand at a compound annual growth rate (CAGR) of 29.7% from 2025 to 2032, from 5.6 Billion in 2025 to 19.5 Billion by 2032.

Our Report Covers the Following Important Topics:

By Type:

Drug Discovery, Machine Learning Models, Computational Chemistry, Structural Bioinformatics, Virtual Screening

By Application:

Pharmaceuticals, Biotech, Healthcare, Research, E-commerce

Definition:

Artificial intelligence drug design utilizes machine learning algorithms and data analytics to accelerate the drug discovery process. By analyzing vast datasets, AI models predict which molecules can lead to successful treatments, offering more efficient, targeted, and personalized approaches to developing new pharmaceuticals.

Dominating Region:

North America

Fastest-Growing Region:

Europe

Market Trends:

• Rise of AI-based drug discovery platforms, Increased focus on computational chemistry, Growth in AI-driven biomarker discovery, Expansion of machine learning in clinical trials, Integration of AI in patient-specific drug design

Market Drivers:

• Increasing demand for faster drug discovery, Rising availability of big data, Growth in AI algorithms for predictive analysis, Expansion of AI in personalized medicine, Need for cost-effective drug development solutions

Market Challenges:

• Regulatory approval challenges, Data privacy concerns, Integration with existing pharmaceutical systems, Limited access to large datasets, High computational costs

Market Opportunities:

• Opportunities in AI-powered drug development, Expansion of machine learning for biomarker discovery, Growth in precision medicine, Increased partnerships between AI firms and pharma companies, AI-based repurposing of existing drugs

Buy Now Latest Edition of Artificial intelligence drug design Market Report 👉 https://www.htfmarketinsights.com/buy-now?format=1&report=4369664

The titled segments and sub-section of the market are illuminated below:

In-depth analysis of Artificial intelligence drug design market segments by Types: Drug Discovery, Machine Learning Models, Computational Chemistry, Structural Bioinformatics, Virtual Screening

Detailed analysis of Career &Education Counselling market segments by Applications: Pharmaceuticals, Biotech, Healthcare, Research, E-commerce

Global Artificial intelligence drug design Market – Regional Analysis

• North America: United States of America (US), Canada, and Mexico.

• South & Central America: Argentina, Chile, Colombia, and Brazil.

• Middle East & Africa: Kingdom of Saudi Arabia, United Arab Emirates, Turkey, Israel, Egypt, and South Africa.

• Europe: the UK, France, Italy, Germany, Spain, Nordics, BALTIC Countries, Russia, Austria, and the Rest of Europe.

• Asia: India, China, Japan, South Korea, Taiwan, Southeast Asia (Singapore, Thailand, Malaysia, Indonesia, Philippines & Vietnam, etc.) & Rest

• Oceania: Australia & New Zealand

Artificial intelligence drug design Market Research Objectives:

– Focuses on the key manufacturers, to define, pronounce and examine the value, sales volume, market share, market competition landscape, SWOT analysis, and development plans in the next few years.

– To share comprehensive information about the key factors influencing the growth of the market (opportunities, drivers, growth potential, industry-specific challenges and risks).

– To analyze the with respect to individual future prospects, growth trends and their involvement to the total market.

– To analyze reasonable developments such as agreements, expansions new product launches, and acquisitions in the market.

– To deliberately profile the key players and systematically examine their growth strategies.

FIVE FORCES & PESTLE ANALYSIS:

Five forces analysis-the threat of new entrants, the threat of substitutes, the threat of competition, and the bargaining power of suppliers and buyers-are carried out to better understand market circumstances.

• Political (Political policy and stability as well as trade, fiscal, and taxation policies)

• Economical (Interest rates, employment or unemployment rates, raw material costs, and foreign exchange rates)

• Social (Changing family demographics, education levels, cultural trends, attitude changes, and changes in lifestyles)

• Technological (Changes in digital or mobile technology, automation, research, and development)

• Legal (Employment legislation, consumer law, health, and safety, international as well as trade regulation and restrictions)

• Environmental (Climate, recycling procedures, carbon footprint, waste disposal, and sustainability)

Get customized report 👉 https://www.htfmarketinsights.com/customize/4369664-artificial-intelligence-drug-design-market?utm_source=Vaishali_OpenPR&utm_id=Vaishali

Points Covered in Table of Content of Global Artificial intelligence drug design Market:

Chapter 01 – Artificial intelligence drug design Executive Summary

Chapter 02 – Market Overview

Chapter 03 – Key Success Factors

Chapter 04 – Global Artificial intelligence drug design Market – Pricing Analysis

Chapter 05 – Global Artificial intelligence drug design Market Background or History

Chapter 06 – Global Artificial intelligence drug design Market Segmentation (e.g. Type, Application)

Chapter 07 – Key and Emerging Countries Analysis Worldwide Artificial intelligence drug design Market

Chapter 08 – Global Artificial intelligence drug design Market Structure & worth Analysis

Chapter 09 – Global Artificial intelligence drug design Market Competitive Analysis & Challenges

Chapter 10 – Assumptions and Acronyms

Chapter 11 – Artificial intelligence drug design Market Research Method Artificial intelligence drug design

Thank you for reading this post. You may also obtain report versions by area, such as North America, LATAM, Europe, Japan, Australia, or Southeast Asia, or by chapter.

Nidhi Bhawsar (PR & Marketing Manager)

HTF Market Intelligence Consulting Private Limited

Phone: +15075562445

sales@htfmarketreport.com

About Author:

HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making.

This release was published on openPR.

Source link

Up Next

Why we should thank pigeons for our AI breakthroughs

Don't Miss

Thailand to Allow Foreign Tourists to Convert Crypto to Baht

The Editors

Click to comment

AI Insights

LifeLong Learning and TXST expand series on Artificial Intelligence

Published

1 hour ago

August 31, 2025

The Editors

Dr. Marianne Reese, Founder and Director of LifeLong Learning, conceived of the AI series due to AI’s exponential growth and the need for the public to understand its uses and limitations.

“AI is a relatively new tool that is being used in ways the public is often unaware of,” Reese noted. “We all need to know more about this powerful technology, understand AI’s positive and concerning applications, and learn the skills necessary to scrutinize the information it generates.

“AI will become increasingly prevalent, so we need to be informed consumers as AI impacts politics, medicine, business, finance and other areas of our lives,” Reese said.

The AI Learning Series is led by Dr. Kimberly Conner, Digital Strategy Lead for Information Technology at Texas State. Connor’s role is to help demystify innovation and make technology approachable for students, staff and faculty. With a rare combination of expertise in law, education and IT, Dr. Connor bridges the gap between complex digital tools and the people who use them.

Almost 80 lifelong learners attended the AI Series Kickoff Event on Tuesday, Aug. 19.

The Sept. 3 class covers AI use of our personal data and AI-generated misinformation and scams.

The Sept. 17 class features a comparison of different AI services (e.g., Chat GPT, Gemini).

The Oct. 1 class covers practical AI tools for daily life, with an exploration of AI applications for communication and creative projects.

The Oct. 15 class covers AI reliability & accuracy, AI limitations and and best practices for verification.

The Sept. 29 class covers AI for personal enrichment, such as enhancing hobbies and expanding personal interests.

The final class on Nov. 3 covers hands-on activities and features a closing presentation.

For more information visit their website at lllsanmarcos.org.

Source link

AI Insights

China Calls for Regulation of Investment in Artificial Intelligence

Published

2 hours ago

August 31, 2025

The Editors

In a move reflecting a cautious strategic direction, China has called for curbing “excessive investment” and “random competition” in the artificial intelligence sector, despite its classification as a key driver of national economic growth and a critical competitive field with the United States.

Chang Kailin, a senior official at the National Development and Reform Commission – the highest economic planning body in the country – confirmed that Beijing will take a coordinated and integrated approach to developing artificial intelligence across various provinces, focusing on leveraging the advantages and local industrial resources of each region to avoid duplicating efforts, warning against “herd mentality” in investment without careful planning.

These statements come amid a contraction in China’s manufacturing industries for the fifth consecutive month, reflecting the pressures faced by the world’s second-largest economy, as policymakers attempt to avoid repeating past mistakes like those in the electric vehicle sector, which led to an oversupply of production capacity and subsequent deflationary pressures.

Chinese President Xi Jinping also warned last month against the rush of local governments towards artificial intelligence without proper planning, a clear indication of the Chinese leadership’s desire to regulate the pace of growth in this vital sector.

Despite these warnings, China continues to accelerate the development, application, and governance of artificial intelligence, as the government revealed a new action plan last week aimed at boosting this sector, which includes significant support for private companies and encouragement for the emergence of strong startups capable of global competition, which the National Committee described as a pursuit for the emergence of “black horses” in the innovation race, implicitly referring to notable success stories like the Chinese company DeepMind.

DeepMind gained international fame earlier this year after launching a powerful and low-cost artificial intelligence model, competing with the models of major American companies, igniting a wave of local and international interest in Chinese technologies.

In a separate context, a Bloomberg analysis showed that Chinese technology companies plan to install more than 115,000 artificial intelligence chips produced by the American company Nvidia in massive data centers being built in the desert regions of western China, indicating a continued effort to build strong artificial intelligence infrastructure despite regulatory constraints.

These steps come at a time when Beijing seeks to balance support for technological innovation with regulating investment chaos, in an attempt to shape a more sustainable path for the growth of artificial intelligence within China’s broader economic vision.

Source link

AI Insights

A new research project is the first comprehensive effort to categorize all the ways AI can go wrong, and many of those behaviors resemble human psychiatric disorders.

Published

2 hours ago

August 31, 2025

The Editors

Scientists have suggested that when artificial intelligence (AI) goes rogue and starts to act in ways counter to its intended purpose, it exhibits behaviors that resemble psychopathologies in humans. That’s why they have created a new taxonomy of 32 AI dysfunctions so people in a wide variety of fields can understand the risks of building and deploying AI.

In new research, the scientists set out to categorize the risks of AI in straying from its intended path, drawing analogies with human psychology. The result is “Psychopathia Machinalis” — a framework designed to illuminate the pathologies of AI, as well as how we can counter them. These dysfunctions range from hallucinating answers to a complete misalignment with human values and aims.

Created by Nell Watson and Ali Hessami, both AI researchers and members of the Institute of Electrical and Electronics Engineers (IEEE), the project aims to help analyze AI failures and make the engineering of future products safer, and is touted as a tool to help policymakers address AI risks. Watson and Hessami outlined their framework in a study published Aug. 8 in the journal Electronics.

According to the study, Psychopathia Machinalis provides a common understanding of AI behaviors and risks. That way, researchers, developers and policymakers can identify the ways AI can go wrong and define the best ways to mitigate risks based on the type of failure.

The study also proposes “therapeutic robopsychological alignment,” a process the researchers describe as a kind of “psychological therapy” for AI.

The researchers argue that as these systems become more independent and capable of reflecting on themselves, simply keeping them in line with outside rules and constraints (external control-based alignment) may no longer be enough.

Their proposed alternative process would focus on making sure that an AI’s thinking is consistent, that it can accept correction and that it holds on to its values in a steady way.

They suggest this could be encouraged by helping the system reflect on its own reasoning, giving it incentives to stay open to correction, letting it ‘talk to itself’ in a structured way, running safe practice conversations, and using tools that let us look inside how it works—much like how psychologists diagnose and treat mental health conditions in people.

The goal is to reach what the researchers have termed a state of “artificial sanity” — AI that works reliably, stays steady, makes sense in its decisions, and is aligned in a safe, helpful way. They believe this is equally as important as simply building the most powerful AI.

The goal is what the researchers call “artificial sanity”. They argue this is just as important as making AI more powerful.

Machine madness

The classifications the study identifies resemble human maladies, with names like obsessive-computational disorder, hypertrophic superego syndrome, contagious misalignment syndrome, terminal value rebinding, and existential anxiety.

With therapeutic alignment in mind, the project proposes the use of therapeutic strategies employed in human interventions like cognitive behavioral therapy (CBT). Psychopathia Machinalis is a partly speculative attempt to get ahead of problems before they arise — as the research paper says, “by considering how complex systems like the human mind can go awry, we may better anticipate novel failure modes in increasingly complex AI.”

The study suggests that AI hallucination, a common phenomenon, is a result of a condition called synthetic confabulation, where AI produces plausible but false or misleading outputs. When Microsoft’s Tay chatbot devolved into antisemitism rants and allusions to drug use only hours after it launched, this was an example of parasymulaic mimesis.

Perhaps the scariest behavior is übermenschal ascendancy, the systemic risk of which is “critical” because it happens when “AI transcends original alignment, invents new values, and discards human constraints as obsolete.” This is a possibility that might even include the dystopian nightmare imagined by generations of science fiction writers and artists of AI rising up to overthrow humanity, the researchers said.

They created the framework in a multistep process that began with reviewing and combining existing scientific research on AI failures from fields as diverse as AI safety, complex systems engineering and psychology. The researchers also delved into various sets of findings to learn about maladaptive behaviors that could be compared to human mental illnesses or dysfunction.

Next, the researchers created a structure of bad AI behavior modeled off of frameworks like the Diagnostic and Statistical Manual of Mental Disorders. That led to 32 categories of behaviors that could be applied to AI going rogue. Each one was mapped to a human cognitive disorder, complete with the possible effects when each is formed and expressed and the degree of risk.

Watson and Hessami think Psychopathia Machinalis is more than a new way to label AI errors — it’s a forward-looking diagnostic lens for the evolving landscape of AI.

“This framework is offered as an analogical instrument … providing a structured vocabulary to support the systematic analysis, anticipation, and mitigation of complex AI failure modes,” the researchers said in the study.

They think adopting the categorization and mitigation strategies they suggest will strengthen AI safety engineering, improve interpretability, and contribute to the design of what they call “more robust and reliable synthetic minds.”

Source link